I can't see any way they go into the conference ca

I can't see any way they go into the conference call or the shareholders meeting without some kind of substantial news. They picked those dates for a reason.

Regarding the Bridge Study, I believe GC mentioned they were adding to the size of the study based on the interim data they reported at C4CT. Hopefully, this won't push results beyond the third quarter or everyone will freak out even more than we've seen. It would be nice for them to give an update on when the enrollment is complete (hopefully it already is). It seems like the most time-consuming part of this study might be the enrollment phase.

If they are really planning revenue guidance for the conference call, you'd think they would have something solid to base it on. I don't know how they can give revenue guidance without even confirming the data is positive.

At this point, I'd love for a big Lympro news item (positive data, partnership, etc) to catch people completely by surprise in the middle of the day. AMBS has become too predictable. Throw in something big about MANF or Elto and the chasing will begin in earnest. It's time the pattern was broken so some of the flippers get caught on the outside looking in.